Table 2.

Treatment-emergent adverse events in healthy subjects following oral semaglutide treatment

	Trial 1	Trial 2
Number of subjects	49	32
Total events [n (%), E]	36 (73.5), 228	27 (84.4), 151
Serious events	0	0
Adverse events occurring in > 10% of subjects in either trial [n (%), E]
Decreased appetite	14 (28.6), 17	21 (65.6), 22
Nausea	20 (40.8), 35	12 (37.5), 21
Diarrhea	8 (16.3), 16	12 (37.5), 18
Fatigue	14 (28.6), 14	4 (12.5), 5
Headache	9 (18.4), 11	7 (21.9), 17
Dyspepsia	9 (18.4), 14	7 (21.9), 8
Vomiting	7 (14.3), 23	6 (18.8), 8
Eructation	4 (8.2), 9	8 (25.0), 8
Abdominal pain	7 (14.3), 9	5 (15.6), 5
Dizziness	11 (22.4), 14	0
Abdominal distension	7 (14.3), 8	3 (9.4), 3
Abdominal discomfort	5 (10.2), 5	4 (12.5), 5
Malaise	7 (14.3), 9	1 (3.1), 1
Nasopharyngitis	1 (2.0), 1	6 (18.8), 6
Constipation	5 (10.2), 9	1 (3.1), 1

E number of adverse events, n number of subjects with an adverse event, % proportion of subjects having an adverse event